These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 21164526)

  • 1. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Misselwitz F
    Nat Rev Drug Discov; 2011 Jan; 10(1):61-75. PubMed ID: 21164526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban, an oral direct factor Xa inhibitor.
    Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
    Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The direct factor Xa inhibitor rivaroxaban.
    Verma AK; Brighton TA
    Med J Aust; 2009 Apr; 190(7):379-83. PubMed ID: 19351313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
    Kreutz R
    Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban: practical considerations for ensuring safety and efficacy.
    Smythe MA; Fanikos J; Gulseth MP; Wittkowsky AK; Spinler SA; Dager WE; Nutescu EA
    Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Abrams PJ; Emerson CR
    Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rivaroxaban: clinical pharmacology].
    Mismetti P; Laporte S
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S16-21. PubMed ID: 19185782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rivaroxaban - Largest Study Program with novel oral anticoagulants].
    van Eickels M
    Dtsch Med Wochenschr; 2015 Jun; 140 Suppl 1():S27. PubMed ID: 26069045
    [No Abstract]   [Full Text] [Related]  

  • 12. [Oral Rivaroxaban (Xarelto)].
    Peeters S; Warnez M
    J Pharm Belg; 2013 Mar; (1):37-40. PubMed ID: 23638611
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral direct factor Xa inhibitor gets FDA's OK.
    Thompson CA
    Am J Health Syst Pharm; 2011 Aug; 68(16):1467. PubMed ID: 21817076
    [No Abstract]   [Full Text] [Related]  

  • 14. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
    Firriolo FJ; Hupp WS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):431-41. PubMed ID: 22668425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM
    Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
    Mousa SA
    Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban).
    Straub A; Roehrig S; Hillisch A
    Curr Top Med Chem; 2010; 10(3):257-69. PubMed ID: 20166954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
    Burghaus R; Coboeken K; Gaub T; Kuepfer L; Sensse A; Siegmund HU; Weiss W; Mueck W; Lippert J
    PLoS One; 2011 Apr; 6(4):e17626. PubMed ID: 21526168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
    Schellong S
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.